Form 8-K - Current report:
SEC Accession No. 0001628280-24-022186
Filing Date
2024-05-09
Accepted
2024-05-09 16:01:30
Documents
15
Period of Report
2024-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sgmo-20240509.htm   iXBRL 8-K 33440
2 EX-99.1 exhibit-991050924.htm EX-99.1 96961
6 GRAPHIC logoa.gif GRAPHIC 43773
  Complete submission text file 0001628280-24-022186.txt   329339

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sgmo-20240509.xsd EX-101.SCH 1943
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sgmo-20240509_lab.xml EX-101.LAB 21880
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sgmo-20240509_pre.xml EX-101.PRE 12547
18 EXTRACTED XBRL INSTANCE DOCUMENT sgmo-20240509_htm.xml XML 2714
Mailing Address 501 CANAL BLVD. RICHMOND CA 94084
Business Address 501 CANAL BLVD. RICHMOND CA 94084 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

EIN.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-30171 | Film No.: 24930292
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)